Venetoclax: Discovery, Development, Safety and Pharmacovigilance
Venetoclax is an oral, selective BCL-2 inhibitor used in specified chronic lymphocytic leukaemia (CLL), small lymphocytic lymphoma (SLL) and acute myeloid leukaemia (AML) settings. It demonstrates a central paradox of targeted cancer therapy: the desired rapid destruction of malignant cells may itself cause life-threatening tumour lysis syndrome (TLS). Safety begins before the first dose, with tumour-burden and renal-risk assessment, rather than after the first suspected reaction. [1,2]
- Venetoclax: Discovery, Development, Safety and Pharmacovigilance
- Discovery: from navitoclax to selective BCL-2 inhibition
- Early clinical development and the TLS lesson
- Pivotal clinical evidence
- Development lessons and indication boundaries
- Newer combination evidence and evolving clinical boundaries
- Authorisation and product lifecycle
- Safety profile and prevention
- Product-specific US and EU listedness
- Practical pharmacovigilance
- Key takeaways
- References
- Regulatory Note
Discovery: from navitoclax to selective BCL-2 inhibition
BCL-2 is a pro-survival protein that restrains mitochondrial apoptosis. In BCL-2-dependent malignancies, disrupting this protection can restore programmed cell death. Earlier BH3-mimetic inhibitors, particularly navitoclax (ABT-263), inhibited both BCL-2 and BCL-XL. Because platelets depend on BCL-XL for survival, navitoclax caused dose-limiting thrombocytopenia. AbbVie/Abbott scientists, with Genentech and academic collaborators, redesigned the chemical series to achieve strong BCL-2 selectivity and spare BCL-XL. ABT-199, later venetoclax, was described in the original Souers and colleagues discovery paper published in January 2013. [3]
Selectivity reduced a specific mechanism-based platelet problem; it did not eliminate marrow toxicity or the danger of rapid tumour killing. The pharmacological rationale and the resulting clinical hazards must be understood together. BCL-2 expression does not alone establish sensitivity in an individual patient, and a molecular mechanism is not a substitute for comparative clinical evidence. [3]
Early clinical development and the TLS lesson
The first-in-human phase 1 CLL/SLL study reported by Roberts and colleagues enrolled 116 patients. In the initial 56-patient dose-escalation cohort, clinical TLS occurred in three patients, including one death. A revised, gradual weekly ramp-up was introduced; no clinical TLS occurred in the subsequent 60-patient expansion cohort. This is evidence that risk-mitigation procedures changed during development, not proof that TLS has been abolished in routine practice. The uncontrolled study established promising activity and informed subsequent trials but could not establish comparative survival benefit. [4]
TLS risk depends on tumour burden, nodal disease, circulating lymphocytes, renal function, baseline biochemistry, treatment phase and interacting drugs. CLL has a distinctive five-week escalation schedule; AML combination regimens use different initiation schedules. A pharmacovigilance review must never transfer one regimen's schedule or laboratory monitoring instructions to another indication. [1,2]
Pivotal clinical evidence
Relapsed CLL: MURANO
In the phase 3 MURANO trial, 389 patients with relapsed or refractory CLL were randomised to fixed-duration venetoclax plus rituximab or bendamustine plus rituximab. Two-year investigator-assessed progression-free survival at the primary analysis was 84.9% versus 36.3%, respectively (hazard ratio 0.17; 95% CI 0.11–0.25). Grade 3–4 neutropenia was more frequent with the venetoclax regimen, so the efficacy benefit must be interpreted alongside marrow toxicity and the differing treatment durations. This trial does not establish superiority over every contemporary targeted regimen. [5]
Previously untreated CLL: CLL14
CLL14 studied 432 previously untreated patients with CLL and coexisting conditions. Fixed-duration venetoclax–obinutuzumab improved progression-free survival compared with chlorambucil–obinutuzumab. The comparator, anti-CD20 partner and baseline population differ from MURANO; pooled adverse-event percentages across these trials would be misleading. [6]
AML: VIALE-A
VIALE-A compared venetoclax plus azacitidine with azacitidine plus placebo in patients with previously untreated AML who were unsuitable for intensive chemotherapy. Median overall survival in the primary analysis was 14.7 versus 9.6 months (hazard ratio 0.66; 95% CI 0.52–0.85). Baseline marrow disease, infections and combination therapy complicate attribution of cytopenias. These findings cannot be generalised to patients fit for intensive induction without additional evidence. [7]
Development lessons and indication boundaries
The development trajectory is not a single uninterrupted sequence of positive studies. The early CLL experience demonstrated profound on-target antitumour activity but also fatal clinical TLS, leading to a slower dose escalation and formalised prophylaxis. Subsequent randomised studies tested specific combinations in different populations: rituximab in relapsed CLL, obinutuzumab in untreated comorbid CLL, and azacitidine in newly diagnosed AML among patients ineligible for intensive induction. Their efficacy endpoints, competing risks, adverse-event denominators and durations of exposure differ. A safety comparison that pools their percentages without accounting for regimen and disease would obscure rather than explain the evidence. [4–7]
The May 2026 US label additionally documents a clinically important negative development experience: increased mortality in a trial adding venetoclax to bortezomib and dexamethasone for multiple myeloma. Section 5.6 advises against this use outside controlled clinical trials. This is a separate indication-specific finding; it does not invalidate the demonstrated benefits in authorised CLL and AML populations, nor establish that all BCL-2 inhibitor combinations carry the same magnitude of risk. [1]
The FDA's 2026 label also includes a CLL/SLL regimen with acalabrutinib, illustrating that the safety profile and administration instructions evolve as combination evidence is incorporated. An assessor must distinguish the active substance's core hazards from those of a particular partner, disease population, sequence and treatment duration. For example, a reported infection during AML therapy can arise from underlying marrow failure, the hypomethylating partner, venetoclax-associated neutropenia or several interacting factors. Recording all plausible contributors is more scientifically defensible than assigning every event to the newest drug. [1]
Newer combination evidence and evolving clinical boundaries
The EU July 2026 product information incorporates additional previously untreated CLL combinations that should not be retroactively attributed to the MURANO or CLL14 populations. The EMA overview identifies a randomised study involving 867 participants comparing venetoclax–acalabrutinib, with or without obinutuzumab, against investigator-selected chemoimmunotherapy. The available efficacy and safety descriptions are specific to these treatment groups; they do not demonstrate that adding a third agent always improves net benefit. The SmPC section 4.8 AMPLIFY safety description reports infections, neutropenia, headache, bruising, diarrhoea and musculoskeletal pain among common events in acalabrutinib-containing combinations, with thrombocytopenia among grade ≥3 events in the triplet group. The attribution problem is especially important because the BTK inhibitor and anti-CD20 antibody have their own adverse-effect profiles. [2,8]
A second newer CLL strategy pairs venetoclax with ibrutinib. The EMA overview summarises a randomised study involving 211 patients and provides progression and survival findings at different follow-up times. These observations concern a fixed regimen and comparator; they are not interchangeable with the rituximab-treated relapsed population in MURANO. For a longitudinal safety review, the relevant questions are whether toxicity changes during lead-in, combination and post-treatment periods, how infections and cytopenias are classified, and whether an event occurred before venetoclax exposure began. [2,8]
Authorisation and product lifecycle
US Venclexta approval began in 2016. EU Venclyxto received conditional marketing authorisation on 5 December 2016, subsequently converted to standard marketing authorisation on 20 November 2018. The development programme involved AbbVie and Genentech/Roche; AbbVie Deutschland GmbH & Co. KG is the EU marketing authorisation holder. The EU July 2026 product information includes previously untreated CLL combinations with acalabrutinib (with or without obinutuzumab) and ibrutinib, in addition to other authorised CLL and AML uses. The US May 2026 label covers adult CLL/SLL and specified AML combinations. A European indication must not be presumed approved in the United States. [1,2]
Safety profile and prevention
Tumour lysis syndrome
Rapid tumour-cell breakdown can produce hyperkalaemia, hyperphosphataemia, hyperuricaemia, hypocalcaemia, acute kidney injury, arrhythmias, seizures and death. The May 2026 US label describes TLS in section 5.1 and risk-dependent prophylaxis, dose escalation and monitoring in section 2. The EU SmPC covers TLS precautions in sections 4.2 and 4.4. Risk assessment must consider renal function and tumour burden, and monitoring must be timed to the relevant dose or restart. The appropriate clinical setting, including inpatient monitoring where indicated, is determined by the current product information and individual risk. [1,2]
For a suspected TLS case, record the exact formulation and regimen, baseline nodal size, absolute lymphocyte count, renal function, urate, potassium, phosphate, calcium, dosing history, prophylaxis, sampling times and outcome. Distinguish laboratory TLS from clinical TLS and preserve the criteria used. An interruption followed by re-initiation can require renewed risk assessment. A post-dose laboratory value without collection time may be insufficient to interpret the sequence.
Neutropenia, infection and bleeding
Neutropenia, febrile neutropenia and serious infections are important safety concerns, especially in combinations. The US label's warnings include neutropenia and infections; its adverse-reaction tables are regimen-specific. AML patients may have profound pretreatment cytopenias, and hypomethylating agents can contribute to marrow suppression. Capture baseline counts, nadir, marrow status, fever, microbiology, organ dysfunction, growth-factor treatment, interruptions and recovery. Do not automatically attribute every infection or cytopenia to venetoclax alone. [1,2]
Drug interactions
Venetoclax is predominantly metabolised by CYP3A. Strong inhibitors can increase exposure and risk, especially during initiation; inducers can lower exposure. The US and EU labels have phase- and indication-specific contraindications, dose-adjustment and avoidance instructions. P-glycoprotein interactions also matter. Document the exact co-medication, start/stop dates, venetoclax schedule, any adjustment and actual administration. A potentially inappropriate combination is not automatically a confirmed medication error without examining the governing instructions and clinical record. [1,2]
Special populations and treatment context
Product information also addresses pregnancy-related embryo-fetal risk, breastfeeding and vaccination considerations. Pregnancy case review should collect exposure timing, other antineoplastics and outcomes without inventing human incidence estimates from animal data. Clinical failure after an interruption should be distinguished from resistance, nonadherence, interaction-driven reduced exposure and progression of underlying disease. [1,2]
Product-specific US and EU listedness
US source: FDA VENCLEXTA oral tablets, NDA 208573, corrected prescribing information revised May 2026, accessed 9 November 2026. Relevant sections are 2, 5, 6, 7 and 8. EU source: EMA Venclyxto film-coated tablets, EMEA/H/C/004106, revision 23, product information updated 8 July 2026, accessed 9 November 2026; SmPC sections 4.2–4.8. The sources cover different authorised regimens and use different safety-table presentations. [1,2]
| Concept | US Venclexta | EU Venclyxto |
|---|---|---|
| TLS | Section 5.1 warning and section 2 prevention/monitoring | Sections 4.2 and 4.4 precautions; 4.8 reaction context |
| Neutropenia | Section 5.2 warning and 6.1 regimen-specific adverse reactions | Section 4.8 undesirable effects and section 4.4 precautions |
| Infection | Section 5.3 warning and 6.1 trial tables | Sections 4.4 and 4.8 |
| Nausea and diarrhoea | Listed in section 6.1 trial adverse-reaction tables | Listed in section 4.8 |
| Anaemia and thrombocytopenia | Regimen-specific section 6.1 adverse reactions | Section 4.8 haematological reactions |
| CYP3A interactions | Sections 2 and 7 | Sections 4.3–4.5 |
US label verification: regimen and event denominator
The FDA's May 2026 corrected VENCLEXTA prescribing information was checked against the original document on 10 November 2026. Its section 6.1 is not a single pooled safety cohort: it separately describes venetoclax with obinutuzumab, rituximab, acalabrutinib, monotherapy and AML combinations. In CLL/SLL the US highlights list neutropenia, thrombocytopenia, anaemia, diarrhoea, nausea, upper respiratory tract infection, cough, musculoskeletal pain, fatigue and oedema among common reactions across the specified regimens; acalabrutinib combination highlights additionally identify headache and COVID-19. In AML combination settings, the common-reaction summary includes febrile neutropenia, pneumonia, sepsis and haemorrhage, among other reactions. These are regimen-dependent US adverse-reaction listings, not a universal venetoclax monotherapy incidence. [1]
The same US document separates warning sections 5.1–5.6 from section 6.1 clinical-trial adverse reactions. Section 5.6 specifically warns of increased mortality when venetoclax was added to bortezomib and dexamethasone for multiple myeloma and states that this use is not recommended outside controlled clinical trials. This negative development finding is essential to the benefit-risk history: activity against BCL-2 does not justify extrapolation to another malignancy or regimen. Section 4 contraindicates strong CYP3A inhibitors during initiation and ramp-up in CLL/SLL; it is inaccurate to describe that as a universal contraindication at every treatment phase or for every indication. [1]
The US label also gives different ramp-up schedules and TLS safeguards for CLL/SLL versus AML, with specific restart risk reassessment after prolonged interruptions. For PV, capture the exact regimen, partner medicines and phase of treatment before interpreting a suspected interaction, TLS or marrow event. The European comparison above remains a selective summary pending independent term-by-term verification of the complete EMA section 4.8 frequency table; it must not be represented as an exhaustive concordance. [1,2]
Verified EU section 4.8: disease-specific adverse-reaction categories
The complete English EMA Venclyxto product-information PDF was independently accessed on 10 November 2026 (document last updated 8 July 2026). Section 4.8 does not report one universal frequency for all venetoclax-treated patients. Its CLL safety overview draws on 1,187 patients in the specified obinutuzumab, ibrutinib, rituximab and monotherapy programmes, while the newer AMPLIFY acalabrutinib cohorts are described separately (291 receiving acalabrutinib–venetoclax and 284 receiving acalabrutinib–venetoclax–obinutuzumab). Its AML safety overview includes 314 patients receiving venetoclax with a hypomethylating agent. These are study-based safety populations, not a single denominator for incidence across CLL and AML. [2]
In the CLL section 4.8 Table 8, pneumonia, upper respiratory tract infection, urinary tract infection, neutropenia, anaemia, lymphopenia, hyperkalaemia, hyperphosphataemia, hypocalcaemia, diarrhoea, vomiting, nausea, constipation and fatigue are classified very common for all grades. Sepsis, febrile neutropenia, tumour lysis syndrome, hyperuricaemia and increased blood creatinine are common for all grades. These classifications reflect the highest observed frequency among the studies specified in the table footnote, not a frequency guaranteed for every regimen. Some terms appear in a different frequency category in the separate grade ≥3 column; do not mistake that column for a second all-grade estimate. [2]
In the AML section 4.8 safety summary, common adverse reactions in the azacitidine combination include thrombocytopenia, neutropenia, febrile neutropenia, nausea, diarrhoea, vomiting, anaemia, fatigue, pneumonia, hypokalaemia and decreased appetite. Serious reactions include febrile neutropenia, pneumonia, sepsis and haemorrhage. The decitabine evidence comes from a different, smaller study, and cannot be assigned the same event denominator. The EU product information presents AML events separately from CLL; do not transfer CLL frequency categories to AML. [2]
| Term and regulatory location | US FDA, May 2026 | EU EMA, July 2026 |
|---|---|---|
| Neutropenia | Section 6.1, across multiple specified CLL/SLL and AML regimen tables; section 5.2 warning | Section 4.8 CLL Table 8: very common (all grades); AML combination safety profile also includes it |
| Pneumonia | Section 6.1, including AML combinations; infection warning in section 5.3 | Section 4.8 CLL Table 8: very common (all grades); AML combination safety profile also includes it |
| Tumour lysis syndrome | Section 5.1 warning, section 2 risk mitigation, with clinical-trial information elsewhere | Section 4.8 CLL Table 8: common (all grades); sections 4.2/4.4 risk mitigation |
| Diarrhoea and nausea | Section 6.1 regimen-specific adverse reactions | Section 4.8 CLL Table 8: very common (all grades); also described for AML combinations |
| Febrile neutropenia | Section 6.1 AML regimen adverse reactions | Section 4.8 CLL Table 8: common (all grades); prominent AML serious reaction |
| Increased creatinine | Assess the actual US section 6.1 laboratory tables for the specific regimen; no universal frequency asserted here | Section 4.8 CLL Table 8: common (all grades) |
Interpretation: These are positively verified listed concepts for the named source and specified section; this table makes no negative claim about unmentioned terms. The US clinical-trial tables use individual regimen populations and their own reporting thresholds. The EU section 4.8 frequency groupings use its pooled and separately presented evidence. A numerical cross-jurisdiction risk comparison would require harmonised population, regimen, ascertainment, follow-up and event definitions. Neither public document alone establishes the company-designated reference safety information for an individual case. [1,2]
EU-specific risk-minimisation and lifecycle implications
The EMA's public product overview identifies additional educational materials for healthcare professionals and patients concerning TLS and a patient card. These are described as EU product-specific risk-minimisation measures; they must not be confused with the US label's requirements or assumed to apply unchanged to all markets. The overview records conditional EU marketing authorisation on 5 December 2016, converted to a standard authorisation on 20 November 2018. This corrects the misleading idea that the original EU authorisation was an ordinary unconditional approval from the outset. [2]
The EMA section 4.2 distinguishes the five-week CLL titration from the three-day AML titration with a hypomethylating agent. It also calls for reassessing TLS risk after interruption, particularly more than one week during CLL titration or more than two weeks after titration. This is a product-information instruction, whereas the case-review questions proposed in this article are educational operational practice. [2]
This is a selective term-level teaching comparison, not an exhaustive concordance. For the terms above, their presence is tied to the cited section; a mention under warnings is not equivalent to an adverse-reaction frequency entry. A term absent from this table cannot be classified as unlisted. US trial percentages and EU frequency categories have different denominators and definitions. For an actual ICSR, use the effective designated reference safety information and exact event term to assess expectedness, independently of causality, seriousness and reportability. [1,2]
Practical pharmacovigilance
Intake and follow-up
The assessor should reconstruct indication, regimen, baseline tumour and renal status, ramp-up stage, co-medications, laboratory monitoring, adverse-event onset, interventions and outcome. Preserve original reporter terminology and measured values with units. Distinguish biochemical abnormalities, clinical syndromes and their complications; the report may support several related coded concepts, but coding should not create diagnoses not established by the evidence.
| Event | Priority information | Alternative or contributing causes |
|---|---|---|
| TLS | Dose step, burden, creatinine, electrolytes, urate, prophylaxis and sampling times | Renal impairment, interacting drugs, restart after interruption |
| Neutropenia | Baseline/nadir ANC, marrow disease, G-CSF, interruptions and recovery | AML, previous cytotoxic treatment, combination partner |
| Febrile neutropenia or sepsis | Fever, cultures, source, organ dysfunction, admission and treatment | Disease-related immune compromise, catheter infection |
| Interaction | Exact CYP3A/P-gp drug, timing, dose adjustment and exposure | Incorrect administration, organ dysfunction |
| Reduced efficacy | Disease markers, adherence, treatment interruptions and interacting inducers | Resistance or progression |
Illustrative restart scenario
A hypothetical CLL patient interrupts venetoclax during ramp-up and subsequently receives an azole antifungal. Restarting the previous dose without rechecking the interruption, current burden and CYP3A interaction could increase TLS risk. The review should reconstruct both drug timelines and the clinical decision, not assume a causal conclusion from temporal proximity. This is an educational scenario, not a real case or dosing instruction. [1,2]
Signal detection and governance
An increase in TLS reports may reflect higher-risk patients, changed prophylaxis, newly common interacting drugs or stimulated reporting. Before a causal inference, review duplicates, case definition, exposure phase, laboratory confirmation and denominators. Spontaneous reporting cannot estimate incidence by itself. For neutropenia and infection, stratify CLL and AML, combination partner, prior therapy and baseline marrow function. Comparative observational evidence may help but requires attention to confounding by disease severity and treatment selection.
Suggested risk-minimisation indicators include documented TLS stratification, prophylaxis, timely monitoring, interaction screening, restart review and cytopenia follow-up. These are proposed operational quality measures, not invented regulatory obligations. Retain source reports, medical assessments, effective reference labels, coding rationale, follow-up and signal decisions. Reconcile reports across hospital pharmacy, patient programmes, partners and product-quality channels while maintaining distinct safety and quality responsibilities.
Source attribution and longitudinal exposure windows
A suspected reaction during combination treatment is not equivalent to a reaction observed during venetoclax monotherapy. A useful longitudinal dataset distinguishes pretreatment disease burden, partner-drug lead-in, venetoclax titration, combination maintenance, treatment interruption and post-discontinuation observation. For each phase, retain the dose actually administered, concomitant antimicrobial prophylaxis, infection history, laboratory sampling and treatment changes. This matters because a cytopenia present before venetoclax may worsen during treatment without becoming solely attributable to it. Conversely, a clinically important interaction may arise when an azole is added months after the original ramp-up. [1,2]
In AML, remission status is particularly important when reviewing cytopenias. The EU SmPC section 4.2 differentiates haematological toxicity before and after remission and discusses cycle delays and reduced duration following prolonged post-remission cytopenias. A case record that says only “dose reduced for neutropenia” conceals the clinical reasoning. Capture marrow evaluation where available, remission status, treatment cycle, count recovery and whether the partner drug was also changed. In CLL, record the intended fixed-duration regimen and whether discontinuation was planned rather than adverse-event driven. These details improve both causality assessment and aggregate comparisons. [1,2]
Inspection-ready risk minimisation
For TLS, an inspection-ready source trail connects the prescribed indication and treatment phase to documented risk stratification, prophylaxis, pre-dose and post-dose biochemistry, decisions on inpatient versus outpatient observation, actual administration and clinical escalation. The European product overview also identifies additional TLS educational materials and a patient card. Evidence that a card was distributed does not by itself demonstrate that high-risk patients received timely laboratory review; process and outcome measures answer different questions. [2,8]
An illustrative deviation would be a missed scheduled post-escalation blood test followed by a laboratory TLS report. The medical assessor should reconstruct the actual sampling timeline and clinical consequences. The quality reviewer should separately establish whether a monitoring instruction applied, what prevented completion and whether a corrective action was effective. This is a hypothetical quality scenario, not a documented inspection finding or proof that an adverse reaction resulted from the missed test.
When apparent safety signals require stratification
For an emerging signal of infection, stratify by AML versus CLL, combination partner, pretreatment neutrophil count, prior therapy, age, treatment phase and available microbiological confirmation. A crude increase in reports after a new indication is added may reflect different patients rather than a changed intrinsic hazard. Similarly, TLS events clustered during re-initiation are a distinct operational question from events during first-dose escalation. Signal documentation should specify the case definition, time at risk, duplicates, missing laboratory data and whether the evidence warrants a regulatory or clinical action. Spontaneous reports alone cannot establish incidence or comparative risk.
Key takeaways
Venetoclax illustrates how molecular selectivity can solve one toxicity mechanism without eliminating clinically important risk. The move from navitoclax reduced BCL-XL-related platelet effects; potent BCL-2 inhibition created an acute TLS hazard that shaped development and dosing. Later trials established benefit in specific CLL and AML populations but require regimen-specific evaluation of cytopenias, infection and interactions. Listedness must be anchored to the precise dated product information, not the INN alone.
References
- US Food and Drug Administration. VENCLEXTA (venetoclax) tablets, NDA 208573, corrected prescribing information, revised May 2026. Sections 1, 2, 5–8. Accessed 9 November 2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/208573s032lblCorrected.pdf
- European Medicines Agency. Venclyxto EPAR and product information, revision 23, updated 8 July 2026. Sections 4.1–4.8. Accessed 9 November 2026. https://www.ema.europa.eu/en/medicines/human/EPAR/venclyxto
- Souers AJ, Leverson JD, Boghaert ER, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013;19:202–208. doi:10.1038/nm.3048. https://www.nature.com/articles/nm.3048
- Roberts AW, Davids MS, Pagel JM, et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374:311–322. doi:10.1056/NEJMoa1513257. https://www.nejm.org/doi/10.1056/NEJMoa1513257
- Seymour JF, Kipps TJ, Eichhorst B, et al. Venetoclax–rituximab in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 2018;378:1107–1120. doi:10.1056/NEJMoa1713976. https://www.nejm.org/doi/10.1056/NEJMoa1713976
- Fischer K, Al-Sawaf O, Bahlo J, et al. Venetoclax and obinutuzumab in patients with CLL and coexisting conditions. N Engl J Med. 2019;380:2225–2236. doi:10.1056/NEJMoa1815281. https://www.nejm.org/doi/10.1056/NEJMoa1815281
- DiNardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383:617–629. doi:10.1056/NEJMoa2012971. https://www.nejm.org/doi/10.1056/NEJMoa2012971
- European Medicines Agency. Venclyxto EPAR medicine overview, last updated 8 July 2026. Conditional-to-standard authorisation history, indications, combination-study overview and additional TLS educational materials. Accessed 10 November 2026. https://www.ema.europa.eu/en/medicines/human/EPAR/venclyxto
Regulatory Note
This is an educational pharmacovigilance reference, not a clinical dosing protocol. Verify the current local product information, regimen, risk-mitigation instructions and effective reference safety information before patient care or formal expectedness decisions. Regulatory indications and safety wording may change.